Alembic Pharmaceuticals has reported results for the fourth quarter and year ended March 31, 2016.
The company has posted a rise of 32.69% its net profit at Rs 89.02 crore for the quarter ended March 31, 2016 as compared to Rs 67.09 crore for the same quarter in the previous year. Total income of the company has increased by 19.65% at Rs 590.96 crore for quarter under review as compared to Rs 493.92 crore for the quarter ended March 31, 2015.
On consolidated basis, the company has posted a rise of 29.65% in its net profit after taxes and share of profit of associates at Rs 91.18 crore for the quarter ended March 31, 2016 as compared to Rs 70.33 crore for the corresponding quarter in the FY15. Total income of the company rose 24.63% at Rs 629.19 crore for quarter under review as compared to Rs 504.83 crore for the same quarter ended previous year.
For the year ended March 31, 2016, the company has posted over two fold jump in its net profit at Rs 698.13 crore as compared to Rs 286.61 crore for the same period in the previous year. Total income of company increased 48.41% at Rs 2997.25 crore for year under review as compared to Rs 2019.57 crore for the period ended March 31, 2015.
For the year ended March 31, 2016, on the consolidated basis, the company has posted over two fold jump in its net profit after taxes and share of profit of associates at Rs 719.44 crore as compared to Rs 282.93 crore for the same period in the previous year. Total income of company has increased by 53.24% at Rs 3154.22 crore for year under review as compared to Rs 2058.42 crore for the period ended March 31, 2015.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1808.50 |
Dr. Reddys Lab | 1342.45 |
Cipla | 1472.45 |
Lupin | 2147.55 |
Zydus Lifesciences | 973.90 |
View more.. |